PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
Gerald F. Watts, Dick C. Chan, Jing Pang, Louis Ma, Qidi Ying, Shashi Aggarwal, Santica M. Marcovina, P. Hugh R. Barrett
Topics & Concepts
AlirocumabPCSK9Apolipoprotein BInternal medicineEndocrinologyLipoproteinStatinLipoprotein(a)KexinChemistryCatabolismEvolocumabLDL receptorMedicineCholesterolMetabolismApolipoprotein A1Lipoproteins and Cardiovascular HealthCerebrovascular and Carotid Artery DiseasesPeripheral Artery Disease Management